Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com

New Steroid Rules for Lupus - Dr. Michelle PetriManagement of CKD in Lupus Nephritis - Dr. HJ AndersHCQ Levels and Adherence - Dr. Nathalie Costedoat-ChalumeauLupus Nephritis Guidelines - a debate - Drs. Michelle Petri and Maria Dall'EraNephrologists Approach to Lupus Nephritis - Dr. Brad RovinVoclosporin and Steroids in Lupus Nephritis - Dr. Jack Cush

In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycophenolate, antiphospholipid syndrome, hypertension management including the differential diagnosis of preeclampsia, practical guidance on pregnancy planning, and optimizing outcomes for patients with lupus. Panelists: Dr. Megan Clowse, Dr. Lisa Sammaritano, Dr. Jill Buyon, Dr. Jack Cush

- QD286: Early Lupus (Dr. Jack Cush) https://youtu.be/zzpC397FhZ0- QD287: A Different Strategy to Tackle Non-adherence (Dr. Megan Clowse)  https://youtu.be/28fhFVM7QRc- QD288: Tackling Lupus Pregnancies (Dr. Bella Mehta) https://youtu.be/zZiGyUTaEF0- QD289: All Swells that Ends Well (Dr. Sheila Reyes) https://youtu.be/ipnSRchKLqY

- QD282: SLE Get Ready (Dr. Jack Cush) https://youtu.be/UWNAxiuwZro- QD283: Rhupus  (Dr. Jack Cush) https://youtu.be/OJUfylWJf4c- QD284: The Dilemma of MMF Without Birth Control (Dr. Megan Clowse)  https://youtu.be/Q1yJrQXyJSU- QD285: Young SLE (Dr. Jack Cush)  https://youtu.be/KigLAeOZciY

- QD279: Hyperpigmentation in Lupus (Dr. Jack Cush) https://youtu.be/xA9nvuadhCg- QD280: Polar Opposite Approaches for Lupus (Dr. Eric Dein) https://youtu.be/zCnF1rgAapk- QD281: Refractory Renal SLE (Dr. Jack Cush)  https://youtu.be/dHS8etnZsRw

Dr. Jack Cush reviews the news and journal reports from RheumNow.com - including views on the vagus nerve, NPSLE and CAR-T mania.  

In this one-hour webinar, panelists discussed antiphospholipid syndrome, including diagnosis, labs, treatment approaches and more. Panelists Dr. Shruti Chaturvedi, Dr. Jason Knight, Dr. Cassy Sims and Dr. Jack Cush

Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow.com.  Interesting trends and results with prednisone in lupus, cannabis in RA and opioid deaths too!

Discussion of the diagnosis, management, and latest insights into cutaneous manifestations of SLE. Panelists: Dr. Victoria P. Werth, Dr. Matilda Nicholas; Dr. Anthony Fernandez; and, Dr. Christopher Richardson.

Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.

In this first webinar of RheumNow's Lupus Unlocked campaign, Journal Club discussed two articles: Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Furie R, et al. NEJM. 2025 Feb 7. doi: 10.1056 Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1) Rovin BH. Lancet. 2021 May 29;397(10289) Speakers:Brad Rovin, MDRichard Furie, MDJack Cush, MD

Dr. Jack Cush reviews the news, articles and drug approvals from the past week on RheumNow.com. This podcast marks the beginning of our Lupus Campaign called "Lupus Unlocked: Keys to Mastery". This months campaign on Lupus is sponsored by Aurinia.

Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Should we believe the reviews and metanalyses?  

Dr. Jack Cush reviews the news and Journal reports from this week on RheumNow.com.  Osteoarthritis patients have unique risks and synovial fluid WBC numbers can tell you when to worry about septic arthritis in gout and pseudogout patients.

Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com  

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. **Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML

Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.